E-mail: sales@rongxinbio.com
Product Categories

Rongxin Bio-Tech Co.,Ltd(H.K.)

FAX: 029-62388781

FEL: +8618220537895

E-mail: sales@rongxinbio.com

Address: Xi'an Jianshe Mansion,China, Shaanxi Sheng, Xian Shi, Yanta Qu, QuJiang ShangQuan, Yanta S Rd

Home > Knowledge > Content
- Apr 02, 2018 -


Composition each tablet contains: Letrozole
Presentation: 2.5mg*100pills
Storage: Keep out of the reach of children; protect from light; store in a cool dry place; do not refrigerate


Letrozole can effectively inhibit the conversion of androgens to estrogens. The estrogens in postmenopausal women are mainly derived from the aromatization of androgen precursors in peripheral tissues, and therefore it is particularly suitable for postmenopausal breast cancer patients. Letrozole has 150 to 250 times more in vivo activity than the first-generation aromatase inhibitor, aminoglutethimide. Due to its high selectivity, without affecting glucocorticoids, mineralocorticoids and thyroid function, high-dose use has no inhibitory effect on the secretion of adrenocortical steroids, and therefore has a higher therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity to systemic systems and target organs, and has good tolerability and strong pharmacological effects. Letrozole has a stronger anti-tumor effect than other aromatase inhibitors and anti-estrogen drugs.



Contact information: